Form 4: HilleVax Acquired by XOMA Royalty for Cash and CVRs

HilleVax, Inc. became a wholly-owned subsidiary of XOMA Royalty Corporation following a tender offer and merger, with shareholders receiving $1.95 cash and one CVR per share.

Summary

• HilleVax, Inc. was acquired by XOMA Royalty Corporation and its subsidiary, XRA 4 Corp., through a tender offer and subsequent merger.
• The merger became effective on September 17, 2025, with HilleVax continuing as a wholly-owned subsidiary of XOMA Royalty Corporation.
• Shareholders received $1.95 in cash and one Contingent Value Right (CVR) for each share of common stock.
• Each CVR represents the right to receive certain contingent cash payments as further described in a CVR Agreement.
• Jeryl L. Hilleman, a director, disposed of 59,224 shares of common stock as a result of the merger.
• Outstanding Restricted Stock Units (RSUs) immediately vested in full and were canceled in exchange for cash equal to $1.95 per underlying share and one CVR for each underlying share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as shareholders received a cash payment and CVRs, providing an exit and potential upside. However, the company ceases to exist independently, and CVR value is uncertain.

Positives

• Shareholders received a guaranteed cash payment of $1.95 per share.
• Shareholders also received Contingent Value Rights (CVRs), offering potential future cash payments based on specific contingencies.
• The acquisition provides a clear liquidity event and exit strategy for HilleVax shareholders.

Negatives

• HilleVax, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.
• Common stock holders no longer have direct equity ownership in HilleVax, Inc.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events and performance, which may not result in significant additional payments.
• Shareholders are exposed to the specific terms and conditions of the CVR Agreement, which dictate the potential for future payments.

Future Outlook

HilleVax, Inc. will continue its operations as a wholly-owned subsidiary of XOMA Royalty Corporation. Its future financial performance and strategic direction will be determined by the new parent company. The realization of value from the Contingent Value Rights (CVRs) is dependent on future contingent cash payments as outlined in the CVR Agreement.

Management Comments

• Jeryl L. Hilleman, a director of HilleVax, Inc., completed the disposition of 59,224 shares of common stock in connection with the merger.

Industry Context

This transaction represents a consolidation event within the biotechnology or pharmaceutical sector, where a larger entity acquires a smaller company. Such acquisitions often aim to integrate promising assets or technologies into a broader portfolio, providing liquidity for the acquired company's investors and potentially accelerating product development under new ownership.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs in exchange for their shares, no longer holding direct equity in HilleVax.
• Employees: HilleVax continues as a subsidiary, implying continuity for employees, though management and operational structures may be integrated under XOMA Royalty Corporation's ownership.
• Customers/Suppliers: Operations are expected to continue under the new ownership, with minimal immediate impact.

Next Steps

• HilleVax, Inc. will operate as a wholly-owned subsidiary of XOMA Royalty Corporation.
• CVR holders will await potential contingent cash payments as per the CVR Agreement.

Key Dates

Recommendation

The company, HilleVax, Inc., has been acquired and is now a wholly-owned subsidiary of XOMA Royalty Corporation. Its common stock is no longer publicly traded. Existing shareholders would have tendered their shares for $1.95 cash and one CVR per share. Therefore, for any remaining shareholders, the recommendation is to complete the tender process or acknowledge the completed sale. There is no longer an opportunity to buy or hold HLVX common stock as a publicly traded entity.

Keywords

HilleVax, HLVX, XOMA Royalty Corporation, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Biotechnology, Corporate Action